Tozuleristide

N/A

Report date: 2026/02/26 20:00:22
NME

Base Information

Drug NameTozuleristide
Drug Alias NameBLZ100CyTP007KNTi0303835-UH424TU
ClassificationDiagnostic agent (In vivo)Small molecules > Synthetic peptide
Mechanisms of ActionDiagnostic imaging enhancers
TargetsNot applicable
Therapy Area/IndicationsOral Squamous Cell CarcinomaSkin NeoplasmsCentral Nervous System Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesBlaze Bioscience Inc
Inactive CompaniesUniversity Of WashingtonBlaze Bioscience Australia Pty Ltd
Active IndicationsCentral Nervous System Neoplasms
Inactive IndicationsOral Squamous Cell CarcinomaSkin NeoplasmsMouth Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A